Altria Market Tracker

Vaping Cancer Risk Evidence

Vaping Cancer Risk Evidence

Key Questions

What evidence links vaping to cancer risks?

Vaping is tied to mouth and lung cancers through DNA damage, inflammation, and mouse tumors (22.5% incidence), with a 20-40 year latency period. Australian UNSW research on March 30, 2026, identified carcinogens in vapes. A comprehensive review confirms these risks.

How do e-cigarettes compare to NRT for quitting?

Oxford studies show e-cigarettes outperform nicotine replacement therapy (NRT) for quitting smoking but still carry risks. ENDS reviews flag cardiovascular and respiratory issues across 69 systematic reviews. This pressures reduced-risk product claims for NJOY and on! versus HTP or snus.

What other health concerns are associated with vaping?

Toddler exposures to vapes surged 243%, now the top nicotine threat for children under five, involving inhalation. Vaping shows risks in low- and middle-income countries with NVP surges. Australian market developments highlight ongoing tobacco product innovations amid these concerns.

Vaping ties to mouth/lung cancers via DNA damage/inflammation/mouse tumors (22.5%), 20-40yr latency; Aus UNSW (3/30/26) carcinogens; Oxford e-cigs >NRT quitting but risks; ENDS review flags CV/respiratory (69 sys reviews). Pressures RRP claims for NJOY/on! vs HTP/snus; toddler exposures +243%, NVPs LMICs surge.

Sources (2)
Updated Apr 8, 2026
What evidence links vaping to cancer risks? - Altria Market Tracker | NBot | nbot.ai